Eleven Stocks Turned $10,000 To $261,421 In 11 Months
- Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
- 11/30/2022
|
Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed
- The company is planting seeds for future growth.
- 11/10/2022
|
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
- The $16.6 billion acquisition shakes up MedTech.
- 11/05/2022
|
Beat the Dow Jones With This Unstoppable Dividend Stock
- Johnson & Johnson has outperformed the Dow so far this year.
- 11/05/2022
|
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ABIOMED, Inc. Buyout
- Wilmington, Delaware--(Newsfile Corp. - November 4, 2022) - Rigrodsky Law, P.A. is investigating ABIOMED, Inc. ("ABIOMED") (NASDAQ: ABMD) regarding possible breaches of fiduciary duties and other violations of law related to ABIOMED's agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, ABIOMED's shareholders will receive $380.00 in cash plus one contingent value right per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-abiomed-inc.To contact Seth D.
- 11/04/2022
|
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT
- NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Corp. (NYSE: ATCO)'s sale to Poseidon Acquisition Corp. for $15.50 per share in cash. If you are an Atlas shareholder, click here to learn more about your rights and options.
- 11/02/2022
|
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.
- 11/01/2022
|
SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.
- NEW YORK , Nov. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson (NYSE: JNJ). Under the tender offer, the Company's shareholders will receive $380.00 in cash, reflecting an enterprise value of approximately $16.6 billion, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 for each share of Abiomed common stock owned.
- 11/01/2022
|
Why Abiomed Stock Skyrocketed Today
- A healthcare titan wants to acquire the medical technology specialist for a whopping $16.6 billion.
- 11/01/2022
|
Abiomed Shares Pop 50% on Johnson & Johnson Buyout
- Marking its biggest deal in nearly six years, Johnson & Johnson ( JNJ , Financial) announced on Tuesday it is buying Abiomed Inc. ( ABMD , Financial) for $16.6 billion in a bid to boost its cardiovascular business even as its spins off its consumer health division.
- 11/01/2022
|
Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript
- Abiomed, Inc. (NASDAQ:ABMD ) Q2 2023 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Jessica Moore - Vice President of Investor Relations, Johnson & Johnson. Joaquin Duato - Chief Executive Officer, Johnson & Johnson Michael Joaquin - Chairman, President and Chief Executive Officer Ashley McEvoy - Executive Vice President and Worldwide Chairman, Medtech Johnson & Johnson Joe Wolk - Chief Financial Officer, Johnson & Johnson Conference Call Participants Joanne Wuensch - Citibank Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Jayson Bedford - Raymond James Terence Flynn - Morgan Stanley Operator Its now pleasure to turn the conference over Vice President of Investor Relations, Jessica Moore.
- 11/01/2022
|
J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion
- The deal would add heart pumps, a fast-growing part of the medical-device industry, to the J&J lineup.
- 11/01/2022
|
Judge blocks Penguin-Simon & Schuster deal, Delta pilots call for strike, J&J to buy Abiomed
- Yahoo Finance anchor Julie Hyman reports the latest headlines including a Judge blocking Penguin-Simon & Schuster deal, Delta pilots calling for strike, J&J planning to buy Abiomed and the Supreme Court blocking Congress from obtaining President Trumps tax returns.
- 11/01/2022
|
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
- Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
- 11/01/2022
|
This medical devices stock opened 50% up on Tuesday: here's why
- ABIOMED Inc (NASDAQ: ABMD) opened about 50% up on Tuesday after Johnson & Johnson (NYSE: JNJ) said it will buy the heart pump maker for $16.6 billion.
- 11/01/2022
|
Abiomed (ABMD) Beats Q2 Earnings Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/01/2022
|
J&J to buy Abiomed in $16.6B deal to boost cardiovascular business
- J&J's cardiovascular devices business will benefit from the $16.6 billion deal to acquire Abiomed. The deal comes at a time when J&J is spinning off its consumer health business.
- 11/01/2022
|
Johnson & Johnson to buy medtech company Abiomed for $380 per share in cash
- Johnson & Johnson is set to buy medical device company Abiomed in cash for $380 per share. CNBC's 'Squawk Box' team breaks down the deal.
- 11/01/2022
|
Abiomed Stock Surges on Johnson & Johnson Takeover
- The pharmaceutical giant will buy the heart-pump maker for $380 a share.
- 11/01/2022
|
Abiomed stock rockets after J&J buyout deal valued at $16.6 billion
- Shares of Abiomed Inc. ABMD, -2.32% rocketed 48.8% toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acquired by Johnson & Johnson JNJ, -0.51% in a deal valued at $16.6 billion. Under terms of the deal, J&J will pay upfront $380 in cash for each Abiomed share outstanding, which represents a 50.7% premium to Monday's closing price of $252.08.
- 11/01/2022
|
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
- 10/28/2022
|
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
- Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
- 10/27/2022
|
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
- Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
- 10/21/2022
|
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
- Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/20/2022
|
Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why
- Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
- 10/07/2022
|
Abiomed: Correction Offers Good Buying Opportunity
- Abiomed's Impella range of micro heart pumps enjoy rising demand in the marketplace. The company's OXY-1 System cardiopulmonary support device has strong growth prospect.
- 09/28/2022
|
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
- Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
- 09/21/2022
|
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
- Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
- 09/19/2022
|
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
- Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- 09/02/2022
|
Abiomed's (ABMD) Impella Favored by Latest Study Result
- Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
- 08/17/2022
|
Why Shares of Abiomed Rose 18.4% in July
- The company's stock rose steadily throughout the month.
- 08/08/2022
|
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript
- Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Research Matt O'Brien - Piper Sandler Mike Polark - Wolfe Research Jayson Bedford - Raymond James Calvin Chu - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Abiomed FY '23 Q1 Earnings Call.
- 08/04/2022
|
Abiomed: Small Premium For Access To ~11% Normalized ROIC
- Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.
- 08/04/2022
|
2 Medical Device Stocks With Extremely High GF Scores
- The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperform. Those stocks with higher GF Scores generally produce higher returns than those with lower GF Scores, according to a backtesting study by GuruFocus.
- 07/18/2022
|
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.
- 07/14/2022
|
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
- Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- 06/17/2022
|
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.
- 05/31/2022
|
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
- Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- 05/16/2022
|
Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/12/2022
|
Abiomed, Inc. (ABMD) CEO Michael Minogue on Q4 2022 Results - Earnings Call Transcript
- Abiomed, Inc. (NASDAQ:ABMD ) Q4 2022 Results Conference Call April 28, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Michael Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Brandon Vazquez - William Blair & Company Danielle Antalffy - SVB Leerink Imron Zafar - Deutsche Bank Michael Polark - Wolfe Research Christopher Cooley - Stephens Inc Operator Hello, and a warm welcome to today's Abiomed Fiscal Year 2022 Fourth Quarter Earnings Call. My name is Emma, and I will be coordinating the call today.
- 04/28/2022
|
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
- Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
- 04/28/2022
|
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
- The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.
- 04/19/2022
|
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
- Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.
- 04/11/2022
|
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.
- 04/08/2022
|
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
- With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade appeared first on InvestorPlace.
- 04/05/2022
|
Abiomed CEO discusses company growth and combining products with supportive technology
- The "Mad Money" host spoke with Abiomed CEO Mike Minogue on Monday's episode of the show.
- 03/28/2022
|
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
- Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- 03/15/2022
|
Got $5,000? 3 Growth Stocks to Buy That Could Double Your Money
- They have a whole lot going right, and little in the way of obstacles.
- 03/12/2022
|
Riding The Stock Waves: Update On The Medical Devices Sector
- Riding The Stock Waves: Update On The Medical Devices Sector
- 02/21/2022
|
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
- Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- 02/11/2022
|
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
- Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
- 02/03/2022
|
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
- Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
- 02/03/2022
|
Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2022
|
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
- Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/20/2022
|
Abiomed (ABMD) Reports Positive Data Backing preCARDIA System
- Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.
- 01/19/2022
|
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022.
- 01/14/2022
|
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
- Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.
- 01/12/2022
|
Has Abiomed (ABMD) Outpaced Other Medical Stocks This Year?
- Here is how Abiomed (ABMD) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
- 12/30/2021
|
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 40th annual J.P. Morgan Healthcare Conference.
- 12/29/2021
|
4 Stocks Growing Earnings Faster Than Sales
- Investors may want to consider the following stocks, since they are growing earnings faster than sales, which may indicate efficient operating activities as profit margins expand along with growth.
- 12/13/2021
|
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
- Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.
- 12/06/2021
|
Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
- Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
- 10/28/2021
|
Abiomed (ABMD) Q2 Earnings Beat Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?
- Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/06/2021
|
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
- Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
- 09/20/2021
|
Abiomed: Impella Will Continue To Drive Revenue Growth
- Abiomed's strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company's Impella range of micro heart pumps will continue to see increasing adoption globally.
- 09/10/2021
|
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
- Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
- 08/19/2021
|
Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag
- The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques.
- 08/18/2021
|
FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump
- DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
- 08/18/2021
|
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
- Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
- 08/13/2021
|
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
- Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
- 08/05/2021
|
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript
- Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript
- 08/05/2021
|
Abiomed (ABMD) Beats Q1 Earnings and Revenue Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 3.77% and 3.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $253 million, up 53% year over year.
- 08/04/2021
|
Abiomed (ABMD) Reports Next Week: Wall Street Expects Earnings Growth
- Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
- Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year.
- 07/13/2021
|
Could This Recently IPOed Medical Device Maker Make You Rich?
- Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.
- 07/03/2021
|
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
- Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.
- 06/30/2021
|
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed's (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular support device with dual-sensor technology. Impella RP with SmartAssist is an innovative advancement of Impella RP, which was granted a PM
- 06/29/2021
|
Abiomed (ABMD) Enters Overbought Territory
- Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- 06/22/2021
|
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
- Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
- 06/03/2021
|
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function. Annually, more than one milli
- 06/01/2021
|
Abiomed to Shareholders: Patience Please, Growth Is On The Way.
- Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.
- 05/04/2021
|
The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts
- People will be getting back to their regular routines when it comes to medical and dental care.
- 05/04/2021
|
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4
- ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
- 04/29/2021
|
Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript
- Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript
- 04/29/2021
|
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 12.73% and 4.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2021
|
Dr. Paula A. Johnson Joins Abiomed Board of Directors
- DANVERS, Mass.--(BUSINESS WIRE)--Dr. Paula Johnson joins the Abiomed Board of Directors
- 04/28/2021
|
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
- Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
- 04/23/2021
|
Abiomed: Valuation Drivers Justify The Premium Over Peers
- Abiomed shares continue their positive outlook, driven by sales momentum in the Impella 5.0 & 5.5 platforms. Excellent balance sheet management with no debt load signals, high free cash conversion, and equity concentrated capital structure.
- 04/21/2021
|
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Asce
- 04/15/2021
|
3 Overlooked Healthcare Stocks to Buy Right Now
- The best is yet to come for each of these companies.
- 04/10/2021
|
Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 29, 2021 the Company will release financial results for the fourth quarter of fiscal 2021.
- 04/08/2021
|
3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis
- 3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis
- 03/30/2021
|
This Company Will Fix the Hidden COVID Danger to Come
- There are long-term implications to the coronavirus pandemic that the market is not appreciating.
- 03/21/2021
|
CMD or ABMD: Which Is the Better Value Stock Right Now?
- CMD vs. ABMD: Which Stock Is the Better Value Option?
- 03/11/2021
|
Could Abiomed Be a Millionaire-Maker Stock?
- This medical device company has revenue growth, patents, and a bright outlook.
- 03/10/2021
|
Abiomed (ABMD) Down 8.6% Since Last Earnings Report: Can It Rebound?
- Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?
- 02/27/2021
|
Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio
- Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.
- 02/11/2021
|
Here's the Surprising Coronavirus Stock You'll Really Want to Own
- It's not a vaccine company, a drugmaker, or a diagnostics company.
- 02/02/2021
|
Abiomed (ABMD) Posts Upbeat Impella SmartAssist Study Results
- The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.
- 02/01/2021
|
Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at explant. A majority of surviving patients recovered their native heart function without needing further mechanical support or a heart transplant. The study is the first large, multicenter experience examining survival rates with Impella 5.5 with SmartAssist support. It was presented at The Society of
- 01/29/2021
|
Nintai Investments 2020 Annual Report
|
Why Abiomed Stock Popped Today
- The company released its latest quarterly report.
- 01/28/2021
|
Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript
- Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript
- 01/28/2021
|
Abiomed (ABMD) Q3 Earnings and Revenues Beat Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 01/28/2021
|
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?
- The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.
- 01/26/2021
|
Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed's robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also protects manufacturing processes and future artificial intelligence algorithms. Abiomed is recognized as a
- 01/07/2021
|
Abiomed: Do Not Fear The Valuation
- Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's intrinsic value, which comes to around ~$340/share, which is quite close to Abiomed's current stock price.
- 01/03/2021
|
Abiomed to Present at the 39th Annual J.P. Morgan Healthcare Conference
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 39th annual J.P. Morgan Healthcare conference.
- 12/29/2020
|
Abiomed's (ABMD) ECMO Technology Completes Successful Treatment
- Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.
- 12/23/2020
|
First Patients, Including a COVID-19 Patient, Treated with Abiomed's Innovative ECMO Technology
- DANVERS, Mass.--(BUSINESS WIRE)--The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.
- 12/21/2020
|
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021
- Four large-cap MedTech stocks are currently flourishing on the back of several positive developments
- 12/18/2020
|
Two Milestones Achieved Toward Small Bore Access with Impella
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has completed the first stage in its U.S. Food and Drug Administration (FDA) early feasibility study (EFS) and the FDA has granted 510(k) clearance to the Impella XR sheath. The Impella XR sheath is a low-profile sheath that expands and recoils, allowing for small bore access and closure with the Impell
- 12/15/2020
|
These 3 Medical Device Stocks Leave Biotech in the Dust
- Biotech stocks simply can't match these reliable returns.
- 11/18/2020
|
Is Abiomed Stock a Buy?
- It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.
- 11/07/2020
|
Here's Why Abiomed Dropped Today
- Revenue bounces back, but growth is still lacking.
- 10/29/2020
|
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript
- Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript
- 10/29/2020
|
First Patients Treated with the World's Smallest Heart Pump, the 9Fr Impella ECP
- DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart's pumping function, providing peak flows greater than 3.5 L/min. The first Impella ECP patient was treated by Amir Kaki, MD, an
- 10/28/2020
|
TCTコネクト発表のデータから、急性心筋梗塞に伴う心原性ショック（AMICS）に対するPCI前のImpella使用が特に女性患者で生存率向上につながると判明
- （ビジネスワイヤ） -- 急性心筋梗塞に伴う心原性ショック（AMICS）患者を対象とした2つの研究で、PCI前にImpellaを留置した場合、PCI後にImpellaを留置した場合と比較して生存率が高いことが明らかになりました。これらの研究結果は、心臓血管研究財団の第32回年次科学シンポジウムである
- 10/23/2020
|
Capital Investment Advisory Services LLC Has $237,000 Stake in ABIOMED, Inc. (NASDAQ:ABMD)
- Capital Investment Advisory Services LLC decreased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 5.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 855 shares of the medical equipment provider’s stock after selling 50 shares during the period. Capital Investment Advisory Services LLC’s […]
- 10/22/2020
|
Restore EF試験でImpella補助下の高リスクPCIが左室駆出率を改善することを証明
- （ビジネスワイヤ） -- Restore EF試験により、 Impella補助下の高リスクPCIでより完全な血行再建を試みたケースを含め、最新のベストプラクティスの使用が、フォローアップ時における左室駆出率（LVEF）、心不全の症状、狭心症の症状の有意な改善をもたらすことが示されました。研究の中間解
- 10/22/2020
|
IBM Retirement Fund Raises Holdings in ABIOMED, Inc. (NASDAQ:ABMD)
- IBM Retirement Fund boosted its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 39.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,439 shares of the medical equipment provider’s stock after purchasing an additional 404 shares during the quarter. IBM […]
- 10/21/2020
|
Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Prä-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer höheren Überlebensrate führt – insbesondere bei Frauen
- Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die Überlebensrate beim Einsatz von Impella vor ein
- 10/19/2020
|
Abiomed : Les données présentées lors du TCT Connect révèlent que l'utilisation de l'Impella avant l'ICP pour le choc cardiogénique lors d'un IAM est associée à un taux de survie plus élevé, en particulier chez les femmes | Zone bourse
|
Größte Studie zu hämodynamisch unterstützten Hochrisiko-PCI-Patienten zeigt: Vollständigere Revaskularisierung mit Impella führt zu besseren Ergebnissen
- Abiomed (NASDAQ: ABMD) meldet neue Daten aus der Studie PROTECT III. Diese zeigen geringere MACCE-Raten (MACCE = Major Adverse Cerebrovascular and Car
- 10/16/2020
|
Abiomed : Selon la plus grande étude réalisée auprès des patients recevant une ICP à risque élevé sous assistance hémodynamique, une revascularisation plus complète avec Impella conduit à l'amélioration des résultats | Zone bourse
|
Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes
- Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarctio
- 10/15/2020
|
Abiomed : L'étude Restore EF démontre qu'une ICP à risque élevé permet d'améliorer la fraction d'éjection ventriculaire gauche à l'aide de la pompe Impella | Zone bourse
|
Crossmark Global Holdings Inc. Decreases Stock Holdings in ABIOMED, Inc. (NASDAQ:ABMD)
- Crossmark Global Holdings Inc. decreased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 4.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,890 shares of the medical equipment provider’s stock after selling 130 shares during the period. Crossmark Global Holdings Inc.’s […]
- 10/14/2020
|
Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction
- The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella-supporte
- 10/14/2020
|
This Medical Device Player Could Be a Top-Notch Pick in 2020 | The Motley Fool
- Abiomed is definitely not cheap, but there is significant upside left in this stock.
- 10/10/2020
|
Chronic Heart Failure Market 2020 Industry Size, Share, Global Analysis, Development Status, Regional Trends, Opportunity Assessment and In-Depth Research Study Till 2025
- Oct 09, 2020 (The Expresswire) --
Global “Chronic Heart Failure Market” is a comprehensive research that provides information regarding Chronic Heart Failure...
- 10/09/2020
|
Abiomed : Le symposium TCT Connect démontrera comment le dispositif Impella permet l'amélioration des résultats pour les patients ICP, en état de choc cardiogénique et d'insuffisance ventriculaire droite à risque élevé | Zone bourse
|
Le symposium TCT Connect démontrera comment le dispositif Impella permet l'amélioration des résultats pour les patients ICP, en état de choc cardiogénique et d'insuffisance ventriculaire droite à risque élevé
- Les avantages d'une revascularisation plus complète avec les pompes cardiaques Impella chez les patients ayant reçu une intervention coronaire percuta
- 10/09/2020
|
Riassunto: TCT Connect per evidenziare come l'impella consente di migliorare i risultati per i pazienti ad alto rischio PCI, shock cardiogeno e scompenso cardiaco destro
- I vantaggi di una rivascolarizzazione più completa con le pompe intracardiache Impella nei pazienti ad alto rischio di intervento coronarico percutane
- 10/08/2020
|
Handelsbanken Fonder AB Makes New Investment in ABIOMED, Inc. (NASDAQ:ABMD)
- Handelsbanken Fonder AB acquired a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,577 shares of the medical equipment provider’s stock, valued at approximately $2,313,000. A number of other institutional investors also […]
- 09/21/2020
|
Glenmede Trust Co. NA Decreases Holdings in ABIOMED, Inc. (NASDAQ:ABMD)
- Glenmede Trust Co. NA reduced its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 15.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,118 shares of the medical equipment provider’s stock after selling 393 shares during the quarter. Glenmede Trust Co. NA’s holdings […]
- 09/18/2020
|
Verition Fund Management LLC Buys New Position in ABIOMED, Inc. (NASDAQ:ABMD)
- Verition Fund Management LLC bought a new stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,365 shares of the medical equipment provider’s stock, valued at approximately $330,000. A number of other hedge funds have […]
- 09/14/2020
|
Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference
- Abiomed to hold fireside chat at the Raymond James North American Equities Conference.
- 09/14/2020
|
These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020 | The Motley Fool
- Some of the names on this list may surprise you.
- 08/27/2020
|
Amalgamated Bank Cuts Holdings in ABIOMED, Inc. (NASDAQ:ABMD)
- Amalgamated Bank decreased its position in ABIOMED, Inc. (NASDAQ:ABMD) by 60.8% in the second quarter, Holdings Channel reports. The institutional investor owned 2,957 shares of the medical equipment provider’s stock after selling 4,591 shares during the period. Amalgamated Bank’s holdings in ABIOMED were worth $714,000 as of its most recent filing with the SEC. A […]
- 08/27/2020
|
Rafferty Asset Management LLC Buys Shares of 2,822 ABIOMED, Inc. (NASDAQ:ABMD)
- Rafferty Asset Management LLC bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,822 shares of the medical equipment provider’s stock, valued at approximately $682,000. A number of other large investors have also recently bought and sold […]
- 08/27/2020
|
1,118 Shares in ABIOMED, Inc. (NASDAQ:ABMD) Purchased by Teza Capital Management LLC
- Teza Capital Management LLC bought a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,118 shares of the medical equipment provider’s stock, valued at approximately $270,000. Several other hedge funds also recently made changes to their […]
- 08/26/2020
|
Global Ischemia Reperfusion Injury Therapeutics Market to Surpass US$ 2,290.1 Million by 2027, Says Coherent Market Insights (CMI)
- North America is expected to be the most lucrative region in the global ischemia reperfusion injury therapeutics market during 2020-2027.
- 08/25/2020
|
The S&P 500's return to a record doesn't tell the full story with 60% of stocks still with losses
- The S&P 500 closed at a record high on Tuesday, wiping out losses from the coronavirus-induced selloff, but new analysis shows most stocks have yet to climb back to prior levels.
- 08/22/2020
|
Martin P. Sutter Sells 750 Shares of ABIOMED, Inc. (NASDAQ:ABMD) Stock
- ABIOMED, Inc. (NASDAQ:ABMD) Director Martin P. Sutter sold 750 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $311.99, for a total value of $233,992.50. Following the completion of the sale, the director now directly owns 187,760 shares of the company’s stock, […]
- 08/22/2020
|
There are a lot more losing than winning stocks in the S&P 500, Jim Cramer says
- "We have a bizarre situation where some companies are doing very well" while "a lot of other companies are getting crushed," the "Mad Money" host said.
- 08/20/2020
|
GRAPHIC-Big Tech drives S&P 500 to record high in coronavirus rally
- The S&P 500 hit a record high on Tuesday, thanks largely to months of outperformance from Amazon and other heavyweight technology companies viewed by investors as likely to emerge from the coronavirus crisis stronger than smaller rivals. The widely followed index's most valuable companies have surged this year, with Apple, Microsoft and Amazon each up between 33% and 72% year to date. ABIOMED, Regeneron Pharmaceuticals and West Pharmaceutical Services, all involved in developing and selling therapies for the coronavirus, have risen over 50% since the S&P 500's previous record high in February.
- 08/18/2020
|
ABIOMED (NASDAQ:ABMD) Price Target Raised to $217.00
- ABIOMED (NASDAQ:ABMD) had its price target hoisted by Morgan Stanley from $152.00 to $217.00 in a report issued on Friday, BenzingaRatingsTable reports. They currently have an underweight rating on the medical equipment provider’s stock. A number of other equities research analysts have also recently commented on ABMD. SVB Leerink lifted their price target on shares […]
- 08/11/2020
|
Impella心臓ポンプ、米国食品医薬品局（FDA）からCOVID-19患者の心臓負荷軽減治療に緊急使用許可を取得
- （ビジネスワイヤ） -- 米国食品医薬品局（FDA）は、ECMO治療中で肺水腫または心筋炎を発症したCOVID-19患者に左心室の負荷軽減と循環補助をするため、心臓左室補助循環デバイスであるImpella（インペラ）心臓ポンプの緊急使用許可（EUA）を与えました。Impellaはアビオメッド（NAS
- 08/11/2020
|
After 150 days of the COVID-19 pandemic, here are the best- and worst-performing stocks
- The tech sector is still in the lead, but consumer-discretionary group trails only slightly.
- 08/10/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abiomed (NASDAQ: ABMD), Alnylam Pharma (NASDAQ: ALNY) and Exelixis (NASDAQ: EXEL) - Markets
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abiomed (ABMD –
- 08/07/2020
|
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1
- ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
- 08/06/2020
|
Abiomed (ABMD) Tops Q1 Earnings and Revenue Estimates
- Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin | | IT Business Net
- June Revenue Up 4% Versus Prior Year DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 20
- 08/06/2020
|
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin
- Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.
- 08/06/2020
|
Abiomed : La FDA délivre une autorisation d'utilisation d'urgence aux pompes cardiaques Impella pour fournir une thérapie de décharge ventriculaire aux patients atteints de COVID-19 | Zone bourse
|
La FDA délivre une autorisation d'utilisation d'urgence aux pompes cardiaques Impella pour fournir une thérapie de décharge ventriculaire aux patients atteints de COVID-19
- La Food and Drug Administration (FDA) américaine vient d'octroyer une autorisation d'utilisation d'urgence (EUA) aux pompes cardiaques Impella pour of
- 08/06/2020
|
Resumen: La FDA emite una autorización de uso de emergencia para las bombas cardíacas Impella y así proporcionar una terapia de descarga a los pacientes de COVID-19
- La Administración de Alimentos y Medicamentos de Estados Unidos (Food and Drug Administration, FDA) ha emitido una autorización de uso de emergencia (
- 08/05/2020
|
Stocks close higher as stimulus talks continue, with Nasdaq notching new high
- Stocks closed modestly higher after a choppy trading session Tuesday, with investors keeping one eye on stimulus talks in Washington and another on mixed...
- 08/04/2020
|
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients
- Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart
- 08/04/2020
|
Coronavirus News: FDA Gives Emergency-Use Authorization To Heart Pump For COVID-19 Patients
- The Impella heart pump from Abiomed treats edema or myocarditis, which can occur in COVID-19 patients.
- 08/04/2020
|
Coronavirus update: U.S. case tally at 4.72 million and New Jersey, Massachusetts and Connecticut see infections climb again
- The U.S. case tally for the coronavirus illness COVID-19 rose by fewer than 50,000 on Monday for a second straight day, data aggregated by Johns Hopkins...
- 08/04/2020
|
ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?
- The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.
- 08/04/2020
|
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients
- Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.Extracorporeal membrane oxygenation (ECMO) is a treatment that uses a pump to circulate blood through an artificial lung back into the bloodstream.COVID-19 causes widespread inflammation which can result in damage to the lungs and heart. This damage may cause severe left ventricular dysfunction manifesting as pulmonary edema and/or myocarditis.According to Abiomed, Impella combined with ECMO therapy has become an important tool for physicians treating COVID-19 patients suffering from both heart and lung failure.This is the second EUA the FDA has granted for Impella during the COVID-19 pandemic. On May 29, the FDA issued an EUA to expand the use of Impella RP to include patients suffering from COVID-19-related right ventricular complications, including right ventricular dysfunction associated with pulmonary embolism.To date, Impella is the only cardiovascular therapeutic device that has received FDA emergency use authorization to treat COVID-19 patients.Shares in Abiomed are rising 2% in Tuesday’s pre-market trading. Year-to-date the stock has soared over 80%, and analysts have a cautiously optimistic Moderate Buy consensus on ABMD’s outlook. Due to the recent rally, the average analyst price target indicates that shares could pull back 24% from current levels.For instance, BTIG analyst Marie Thibault has a hold rating on the stock writing “We remain at Neutral due to valuation.” She notes that during the pandemic, ABMD has been emphasizing its education and training efforts which may help boost Impella utilization once the pandemic reaction passes.“Layering on additional clinical trial work, pipeline products, and the potential for M&A, we believe Abiomed is poised to gradually return to strong sustainable growth” she tells investors.Ultimately however, Thibault believes this that much of this optimism is already priced in. “ABMD’s share price has risen alongside much of MedTech and the stock trades at a premium EV/Sales multiple versus the fast-growing comp group average” the analyst concludes. (See ABMD stock analysis on TipRanks).Related News: Merck, Novocure Team Up On Lung Cancer Treatment; Trial Set For 2H20 AstraZeneca-Merck Pancreatic Cancer Drug Wins European Approval Regeneron: Covid-19 Antibody Combo Prevents & Treats Disease In Animals More recent articles from Smarter Analyst: * Tyson Foods’ 3Q Earnings Top Estimates; Names New CEO * Merck, Hanmi Seal Licence Deal For Fatty Liver Disease Therapy * TikTok Parent ByteDance Accuses Facebook Of ‘Plagiarism And Smear’ * McKesson Beats 2Q Estimates, UBS Lifts PT
- 08/04/2020
|
5 things to know before the stock market opens on Tuesday
- U.S. stock futures traded slightly lower on Tuesday as Wall Street took a breather following sharp gains in the previous session.
- 08/04/2020
|
Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients
- Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures. COVID-19, the respiratory disease caused by the new coronavirus, causes widespread inflammation which could impair or damage the left ventricle of the heart and lead to heart failure or excess fluids in the lungs. Impella, part of a family of invasive heart pump devices manufactured by Abiomed, provides circulatory support to patients who develop left side ventricular failure and is authorized to be used by healthcare providers in the hospital setting.
- 08/04/2020
|
Global deaths surpass 700,000; Vietnam reports further rise of infections
- The coronavirus has infected more than 18.5 million people around the world as of Wednesday, killing at least 701,085 people.
- 08/04/2020
|
Abiomed's stock rises on second COVID-19-related EUA for heart pump
- Shares of Abiomed Inc. undefined rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use...
- 08/04/2020
|
Abiomed's stock rises on second COVID-19-related EUA for heart pump
- Shares of Abiomed Inc. rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use authorization from the Food and Drug Administration as a treatment for some COVID-19 patients. The heart pump can be used for patients who have heart or lung damage as a result of an infection with the coronavirus. This is the second time the FDA has authorized the pump for use in COVID-19 patients; in May, the FDA issued an EUA for patients suffering from COVID-19-related right ventricular complications. Abiomed's stock is up 80.7% year-to-date, while the S&P 500 is up 1.9%.
- 08/04/2020
|
FDA approves Abiomed heart pump to treat coronavirus patients
- The Food and Drug Administration has approved the emergency use of Abiomed's Impella heart pump for Covid-19 patients with heart failure.
- 08/04/2020
|
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis. Impella is manufactured by Abiomed (NASDAQ: ABMD).
- 08/04/2020
|
Zurcher Kantonalbank Zurich Cantonalbank Reduces Position in ABIOMED, Inc. (NASDAQ:ABMD)
- Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 30.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,742 shares of the medical equipment provider’s stock after selling 3,787 shares during the quarter. Zurcher Kantonalbank Zurich […]
- 08/04/2020
|
Janney Montgomery Scott LLC Cuts Stake in ABIOMED, Inc. (NASDAQ:ABMD)
- Janney Montgomery Scott LLC cut its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 3.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,893 shares of the medical equipment provider’s stock after selling 180 shares during the quarter. Janney Montgomery Scott […]
- 08/04/2020
|
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide lef
- 08/04/2020
|
Große Multicenter-Studie in Japan findet hohe Überlebensraten bei Verwendung von Impella Herzpumpen
- Eine dreijährige, von Prüfern geleitete prospektive Studie an japanischen Patienten mit einer Impella Herzpumpe stellte beim Einsatz von Impella bei P
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
How Much Is Abiomed, Inc. (NASDAQ:ABMD) Paying Its CEO?
- This article will reflect on the compensation paid to Mike Minogue who has served as CEO of Abiomed, Inc...
- 07/31/2020
|
Abiomed : Une importante étude multicentrique au Japon démontre des taux élevés de survie avec la pompe cardiaque Impella | Zone bourse
|
Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump
- A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%. The study, conducted with oversight by 10 Japanese professional societies, including the Japanese Circulation Society (JCS), is the first to use the Japanese Registry for Percutaneous Ventricular Assist Devices (J-PVAD) to investigate the efficacy and safety of Impella. J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA). Lead investigator Yoshiki Sawa M.D., Ph.D., presented the interim analysis today as a late-breaking clinical study at the Annual Scientific Meeting of JCS.
- 07/30/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 23)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Acceleron Pharma Inc (NASDAQ: XLRN)
Aerpio...
- 07/24/2020
|
Abiomed: Current Momentum Looks Sustainable After Year Of Controversy
- Abiomed's share price has grown impressively since the March market sell-off, on solid sales and progress of its Impella heart pump product range.
- 07/22/2020
|
FMS vs. ABMD: Which Stock Should Value Investors Buy Now?
- FMS vs. ABMD: Which Stock Is the Better Value Option?
- 07/22/2020
|
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 21)
ABIOMED, Inc. (NASDAQ: ABMD)
Assembly Biosciences Inc (NASDAQ: ASMB)
Bio-Rad Laboratories, Inc. (NYSE: BIO)...
- 07/22/2020
|
Abiomed Gets FDA Nod for Data Streaming Via Impella Connect
- Abiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.
- 07/20/2020
|
Harel Insurance Investments & Financial Services Ltd. Invests $225,000 in ABIOMED, Inc. (NASDAQ:ABMD)
- Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 930 shares of the medical equipment provider’s stock, valued at approximately $225,000. Other hedge funds and other institutional […]
- 07/16/2020
|
Abiomed : La FDA approuve la transmission de données en continu depuis la console Impella, ouvrant la voie aux algorithmes d'intelligence artificielle afin d'améliorer encore plus l'état de santé des patients | Zone bourse
|
Abiomed First Quarter Fiscal 2021 Earnings and Conference Call Notification
- Abiomed announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021.
- 07/16/2020
|
Samenvatting: FDA keurt gegevensstreaming vanuit de Impella-console goed en zet de toon voor kunstmatige intelligentie-algoritmen om de patiëntresultaten verder te verbeteren
- De Amerikaanse Food and Drug Administration (FDA) heeft eenzijdige digitale datastreaming goedgekeurd tijdens patiëntenondersteuning door Abiomed’s (N
- 07/16/2020
|
ABIOMED (NASDAQ:ABMD) Rating Increased to Positive at OTR Global
- OTR Global upgraded shares of ABIOMED (NASDAQ:ABMD) to a positive rating in a research note released on Monday morning, The Fly reports. ABMD has been the subject of a number of other reports. SVB Leerink boosted their price objective on ABIOMED from $195.00 to $225.00 and gave the company a market perform rating in a […]
- 07/14/2020
|
State of Alaska Department of Revenue Grows Position in ABIOMED, Inc. (NASDAQ:ABMD)
- State of Alaska Department of Revenue boosted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 2.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,994 shares of the medical equipment provider’s stock after purchasing an additional 226 shares during the quarter. State of Alaska Department […]
- 07/13/2020
|
Did Hedge Funds Make The Right Call On ABIOMED, Inc. (ABMD) ?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/12/2020
|
Short Interest in ABIOMED, Inc. (NASDAQ:ABMD) Declines By 13.6%
- ABIOMED, Inc. (NASDAQ:ABMD) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 2,360,000 shares, a drop of 13.6% from the June 15th total of 2,730,000 shares. Currently, 5.4% of the shares of the company are short sold. Based on an average daily volume […]
- 07/07/2020
|
Xenon Lights Market Trajectory & Analytics to 2027 - COVID-19 Updated - ResearchAndMarkets.com
|
Abiiomed: Lots Of Growth Ahead (NASDAQ:ABMD)
- The expanding market opportunity and superior financial metrics has me bullish on Abiomed. Even with an economic slowdown, I expect Abiomed to grow net profits by 15% annually due to the continued adoption of their Impella solution globally.
- 07/06/2020
|
ABIOMED, Inc. (NASDAQ:ABMD) Receives $186.40 Average PT from Analysts
- ABIOMED, Inc. (NASDAQ:ABMD) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation […]
- 07/06/2020
|
Comparing ABIOMED (NASDAQ:ABMD) & Titan Medical (NASDAQ:TMDI)
- Titan Medical (NASDAQ:TMDI) and ABIOMED (NASDAQ:ABMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings. Institutional and Insider Ownership 4.1% of Titan Medical shares are held by institutional investors. Comparatively, 94.4% of […]
- 07/03/2020
|
MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings
- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP (“Hayfin”), and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Company’s board as preferred directors.
- 07/02/2020
|
Stay-at-home orders helped lift several Mass. stocks in the first half of 2020 - The Boston Globe
- We are in a Work From Home World, and Wall Street knows it.
- 07/02/2020
|
Axa Grows Stock Holdings in ABIOMED, Inc. (NASDAQ:ABMD)
- Axa increased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 16.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 198,799 shares of the medical equipment provider’s stock after buying an additional 28,808 shares during the quarter. Axa owned about 0.44% […]
- 07/02/2020
|
Laut Studie beträgt die Überlebensrate von Patienten mit kardiogenem Schock und weiteren schwere Herzerkrankungen 84 % mit der neuen Herzpumpe Impella 5.5 mit SmartAssist
- Laut der ersten in den USA veröffentlichten Studie von Patienten, die die neueste Herzpumpe von Abiomed, die Impella 5.5 mit SmartAssist, erhalten hab
- 07/02/2020
|
Abiomed : Une étude révèle un taux de survie de 84 % chez des patients en état de choc cardiogénique ou atteints d'autres cardiopathies complexes avec la nouvelle pompe Impella 5.5 équipée de SmartAssist | Zone bourse
|
Abiomed : Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist | MarketScreener
|
Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist
- The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal.
- 07/01/2020
|
These stocks, including Tesla and Apple, are the real winners for the second quarter of 2020
- A select group of stocks rose in the second quarter and for all of 2020.
- 07/01/2020
|
Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist
- The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the pati
- 07/01/2020
|
Goldman Says Tech Valuations to Remain Intact if Rates Go Higher
- Goldman Says Tech Valuations to Remain Intact if Rates Go Higher
- 06/30/2020
|
